- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bioxytran Reports Positive Phase 2 Results for ProLectin-M
Rapid viral clearance demonstrated in 100% of treated subjects by Day 7
Feb. 11, 2026 at 10:23pm
Got story updates? Submit your updates here. ›
Bioxytran, Inc. announced positive results from a Phase 2 clinical trial evaluating its antiviral drug candidate ProLectin-M. The randomized, double-blind, placebo-controlled study showed complete elimination of viral load in 100% of patients treated with ProLectin-M by Day 7, compared to the placebo group.
Why it matters
ProLectin-M's novel mechanism of action, which targets viral entry at the cell surface rather than viral replication, represents a fundamentally different approach to antiviral therapy. These results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology.
The details
The Phase 2 trial enrolled 38 subjects with acute viral infection. Subjects were randomized to receive one of three ProLectin-M dose levels or a placebo over a seven-day treatment period. Viral shedding was assessed using RT-PCR, with viral clearance defined as non-detection of viral RNA. The study demonstrated complete viral elimination in 100% of treated subjects by Day 7, compared to the placebo group (p=.001). No viral rebounds were observed during the 14-day post-treatment observation period.
- On Day 3, 1 of 38 subjects demonstrated non-detection of viral shedding.
- On Day 5, 16 of 38 subjects demonstrated non-detection of viral shedding.
- On Day 7, 38 of 38 subjects demonstrated non-detection of viral shedding.
The players
Bioxytran, Inc.
A clinical-stage biotechnology company developing novel carbohydrate-based therapeutics, including the lead program ProLectin-M.
Dr. Leslie Ajayi
Chief Medical Officer of Bioxytran.
Dr. David Platt
Chief Scientific Officer of Bioxytran.
What they’re saying
“The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by Day 7.”
— Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran
“What continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action. Rather than targeting viral replication inside the cell, our galectin antagonist is designed to interfere with viral entry at the cell surface. This extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy.”
— Dr. David Platt, Chief Scientific Officer of Bioxytran
What’s next
Based on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.
The takeaway
Bioxytran's ProLectin-M demonstrates a novel approach to antiviral therapy by targeting viral entry rather than replication, leading to rapid and sustained viral clearance in this Phase 2 trial. These results support the potential of carbohydrate-based therapeutics in addressing significant unmet needs in virology.
